keyword
https://read.qxmd.com/read/38564601/confocal-laser-endomicroscopy-as-predictive-biomarker-of-clinical-and-endoscopic-efficacy-of-vedolizumab-in-ulcerative-colitis-the-detect-study
#21
JOURNAL ARTICLE
Lucille Quénéhervé, Caroline Trang-Poisson, Aurélie Fantou, Mathurin Flamant, Tony Durand, Guillaume Bouguen, Jérémy Bregeon, Thibauld Oullier, Morgane Amil, Marie Dewitte, Stéphanie Bardot, Stéphanie Blandin, Cécile Braudeau, Marie-Anne Vibet, Régis Josien, Michel Neunlist, Arnaud Bourreille
AIMS: In patients with ulcerative colitis (UC), no biomarker is available to help the physician to choose the most suitable biotherapy. The primary objective of this pilot study was to assess the feasibility of identification of α4β7- and TNF-expressing cells, to predict the response to vedolizumab using confocal laser endoscopy (CLE). METHODS: Patients with moderate-to-severe UC, naïve of biotherapy, received vedolizumab. Clinical evaluation was performed at each infusion...
2024: PloS One
https://read.qxmd.com/read/38556226/polysaccharides-from-an-edible-mushroom-hericium-erinaceus-alleviate-ulcerative-colitis-in-mice-by-inhibiting-the-nlrp3-inflammasomes-and-reestablish-intestinal-homeostasis
#22
JOURNAL ARTICLE
Hao Li, Jiaxin Feng, Chang Liu, Shuting Hou, Junlong Meng, Jing-Yu Liu, Sun Zilong, Ming-Chang Chang
This study aimed to assess the effects of polysaccharides extracted from Hericium erinaceus fruiting bodies (HEFPs) on the inflammatory response to oxidative stress in a mouse model of ulcerative colitis (UC) induced by ingestion of dextran sodium sulfate. The results indicated reduced oxidative damage in the HEFPs groups, as evidenced by significantly decreased malondialdehyde levels and significantly increased levels of the antioxidant enzymes superoxide dismutase and catalase in colon homogenates, compared with those in the Model Control (MC) group...
March 29, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38556033/antibiotic-use-in-the-12-months-prior-to-ileal-pouch-anal-anastomosis-increases-the-risk-for-pouchitis
#23
JOURNAL ARTICLE
Edward L Barnes, Anastasia Karachalia Sandri, Hans H Herfarth, Tine Jess
BACKGROUND & AIMS: Pouchitis is the most common complication after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC), however clinical and environmental risk factors for pouchitis remain poorly understood. We explored the relationship between specific clinical factors and the incidence of pouchitis. METHODS: We established a population-based cohort of all adult persons in Denmark undergoing proctocolectomy with IPAA for UC from 1996-2020. We used Cox Proportional Hazard modeling to assess the impact of antibiotic, non-steroidal anti-inflammatory drug (NSAID) exposure, and appendectomy on diagnosis of acute pouchitis in the first 2 years after IPAA surgery...
March 29, 2024: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/38553192/an-inulin-type-fructan-cp-a-from-codonopsis-pilosula-attenuates-experimental-colitis-in-mice-by-promoting-autophagy-mediated-inactivation-of-nlrp3-inflammasome
#24
JOURNAL ARTICLE
Jiangtao Zhou, Jun Wang, Jiajing Wang, Deyun Li, Jing Hou, Jiankuan Li, Yun'e Bai, Jianping Gao
Inulin-type fructan CP-A, a predominant polysaccharide in Codonopsis pilosula, demonstrates regulatory effects on immune activity and anti-inflammation. The efficacy of CP-A in treating ulcerative colitis (UC) is, however, not well-established. This study employed an in vitro lipopolysaccharide (LPS)-induced colonic epithelial cell model (NCM460) and an in vivo dextran sulfate sodium (DSS)-induced colitis mouse model to explore CP-A's protective effects against experimental colitis and its underlying mechanisms...
March 2024: Chinese Journal of Natural Medicines
https://read.qxmd.com/read/38542929/oral-delivery-of-astaxanthin-via-carboxymethyl-chitosan-modified-nanoparticles-for-ulcerative-colitis-treatment
#25
JOURNAL ARTICLE
Wen Zhang, Xinping Zhang, Xinyi Lv, Ao Qu, Wenjing Liang, Limin Wang, Pei Zhao, Zijian Wu
The oral delivery strategy of natural anti-oxidant and anti-inflammatory agents has attracted great attention to improve the effectiveness of ulcerative colitis (UC) treatment. Herein, we developed a novel orally deliverable nanoparticle, carboxymethyl chitosan (CMC)-modified astaxanthin (AXT)-loaded nanoparticles (CMC-AXT-NPs), for UC treatment. The CMC-AXT-NPs were evaluated by appearance, morphology, particle size, ζ-potential, and encapsulation efficiency (EE). The results showed that CMC-AXT-NPs were nearly spherical in shape with a particle size of 34...
March 14, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38537445/novel-applications-of-yinhua-miyanling-tablets-in-ulcerative-colitis-treatment-based-on-metabolomics-and-network-pharmacology
#26
JOURNAL ARTICLE
Caixia Wang, Hui Yu, Zhuoqiao Li, Junzhe Wu, Peng Gao, Shanmei He, Daohao Tang, Qianyun Wang, Hanlin Liu, Haoming Lv, Jinping Liu
BACKGROUND: Yinhua Miyanling tablets (YMT), comprising 10 Chinese medicinal compounds, is a proprietary Chinese medicine used in the clinical treatment of urinary tract infections. Medicinal compounds, extracts, or certain monomeric components in YMT all show good effect on ulcerative colitis (UC). However, no evidence supporting YMT as a whole prescription for UC treatment is available. PURPOSE: To evaluate the anti-UC activity of YMT and elucidate the underlying mechanisms...
January 15, 2024: Phytomedicine
https://read.qxmd.com/read/38530500/effect-of-tofacitinib-on-one-year-colectomy-risk-in-anti-tnf-refractory-ulcerative-colitis-a-prospective-multicenter-italian-study
#27
JOURNAL ARTICLE
Anna Maria Carvalhas Gabrielli, Francesca Ferretti, Camilla Maria Monico, Enrico Tombetti, Giovanni Maconi, Samanta Romeo, Nicole Piazza O Sed, Flavio Caprioli, Anna Maria Mazzola, Saverio Alicante, Roberto Bertè, Elisabetta Lolli, Maria Lia Scribano, Elisabetta Buscarini, Chiara Ricci, Stefania Carmagnola, Sandro Ardizzone, Rosanna Cannatelli
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor recently approved to induce and maintain remission in ulcerative colitis (UC). AIMS: Considering the number of anti-TNF non-responders, this study aims to assess the effectiveness and safety of tofacitinib in a cohort of multi-failure patients with moderate-to-severe UC at 52 weeks. METHODS: From January 2021 to March 2023, we performed a prospective multicenter study observing adult patients with moderate-to-severe UC starting tofacitinib after an anti-TNF failure for a 52-week-long period...
March 26, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38528940/risk-of-primary-gastrointestinal-lymphoma-in-patients-with-inflammatory-conditions-exposed-to-tumor-necrosis-factor-alpha-inhibitors-and-immunomodulators-a-case-control-study
#28
JOURNAL ARTICLE
Manuel B Braga-Neto, Jason Nasser, Xiao Xing Iris Wang, William Scott Harmsen, Laura E Raffals, Michael Camilleri, Victor Chedid
INTRODUCTION: The aim of this case-control study was to determine if exposure to tumor necrosis factor alpha inhibitors (TNFIs) or immunomodulators (thiopurines or methotrexate) was associated with development of primary gastrointestinal lymphoma (PGIL) in patients with chronic inflammatory conditions. METHODS: Patients with PGIL and controls evaluated at a tertiary care center over 20 years were matched 1:3 using a medical record informatics search engine based on their chronic inflammatory condition (Crohn's disease [CD], ulcerative colitis [UC], rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and duration of follow-up...
January 2024: Crohn's & colitis 360
https://read.qxmd.com/read/38525396/therapeutic-effects-of-tretinoin-and-caffeine-treated-bone-marrow-derived-mesenchymal-stem-cell-on-immunological-features-of-ulcerative-colitis-an-animal-model-study
#29
JOURNAL ARTICLE
Behnaz Movaffaghbani, Hadi Esmaeili Gouvarchinghaleh, Mahdieh Farzanehpour, Jalal Shayegh
BACKGROUND: Ulcerative colitis (UC) is one of the inflammatory gastrointestinal diseases. It causes irritation, inflammation, and ulcers in the digestive tract. UC is distinguished clinically by abdominal and rectal pain and intestinal secretion abnormalities. Mesenchymal stem cell (MSC) therapy could be the underlying treatment for UC. This study aimed to compare the results of MSC therapy with tretinoin and caffeine in an animal model. MATERIALS AND METHODS: Sixty male BALB/c mice were randomly divided into six equal groups...
2024: Advanced Biomedical Research
https://read.qxmd.com/read/38524263/paradoxical-reaction-and-parastomal-pyoderma-gangrenosum-emergence-with-secukinumab-therapy
#30
Anas Zaher, Michael Castillo
Paradoxical reactions are characterized by the emergence or worsening of a pathological condition that typically responds to the administered drug while treating the patient for another condition. Certain drugs, such as tumor necrosis factor inhibitors, can induce pyoderma gangrenosum. Recently, the drug secukinumab has been implicated in a few case reports as a potential cause of pyoderma gangrenosum after initiation. We report the first case of biologic-refractory ulcerative colitis presenting with parastomal pyoderma gangrenosum after the initiation of secukinumab...
March 2024: ACG Case Reports Journal
https://read.qxmd.com/read/38522565/astragalus-polysaccharides-ameliorates-experimental-colitis-by-regulating-memory-b-cells-metabolism
#31
JOURNAL ARTICLE
Yifei Deng, Lizhao Song, Jiaqi Huang, Wen Zhou, Yali Liu, Xiuyun Lu, Haimei Zhao, Duanyong Liu
It is well-established that the reduced Memory B cells (MBCs) play an important role in the pathogenesis of ulcerative colitis (UC), rendering them a potential therapeutic target for UC intervention. Astragalus polysaccharide (APS), a primary active constituent derived from the classic traditional Chinese medicine Astragalus membranaceus (AM), has been used for centuries in the treatment of UC in both human and animal subjects due to its renowned immunomodulatory properties. However, it is unknown whether APS can regulate MBCs to alleviate experimental colitis...
March 22, 2024: Chemico-biological Interactions
https://read.qxmd.com/read/38520575/exploring-the-therapeutic-potential-of-anastatica-hierochuntica-essential-oil-in-dss-induced-colitis
#32
JOURNAL ARTICLE
Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Mohammed Alqudah, Muna Oqal, Rawan Abudalo, Shtaywy S Abdalla
The aim of this investigation was to explore the protective impacts and mechanisms of Anastatica hierochuntica essential oil (EOAH) against dextran sulfate sodium (DSS)-induced experimental colitis in mice. EOAH demonstrated a reduction in DSS-induced body weight decline, disease activity index (DAI), colon length reduction, colonic tissue damage, and myeloperoxidase (MPO) activity. The essential oil significantly mitigated the production of pro-inflammatory agents including TNF-α, IL-1β, and IL-12...
March 23, 2024: Inflammopharmacology
https://read.qxmd.com/read/38517042/investigating-the-association-between-the-tissue-expression-of-mirna-101-jak2-stat3-with-tnf-%C3%AE-il-6-il-1%C3%AE-and-il-10-cytokines-in-the-ulcerative-colitis-patients
#33
JOURNAL ARTICLE
Qazaleh Voshagh, Amir Anoshiravani, Amin Karimpour, Golnaz Goodarzi, Sadra Samavarchi Tehrani, Ozra Tabatabaei-Malazy, Ghodratollah Panahi
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease caused by numerous factors, such as immune system dysfunction and genetic factors. MicroRNAs (miRNAs) play a crucial role in UC pathogenesis, particularly via the JAK-STAT pathway. Our aim was to investigate the association between miRNA-101 and JAK2-STAT3 signaling pathway with inflammatory cytokines in UC patients. METHODS: We enrolled 35 UC patients and 35 healthy individuals as the control group, referred to Shariati Hospital, Tehran, Iran...
March 2024: Immunity, Inflammation and Disease
https://read.qxmd.com/read/38507609/lack-of-atp2b1-in-cd4-t-cells-causes-colitis
#34
JOURNAL ARTICLE
Amarsanaa Javkhlant, Kensuke Toyama, Yasunori Abe, Joshua M Spin, Masaki Mogi
BACKGROUND: The ATP2B1 gene encodes for a calcium pump, which plays a role in removing Ca2+ from cells and maintaining intracellular Ca2+ homeostasis. Reduction of the intracellular Ca2+ concentration in CD4+ T cells is thought to reduce the severity of colitis, while elevation of Ca2+ in CD4+ T cells induces T cell hyperactivity. Our aim was to clarify the role of ATP2B1 in CD4+ T cells and in inflammatory bowel disease development. METHODS: A murine CD4+ T cell-specific knockout (KO) of ATP2B1 was created using a Cre-loxP system...
March 20, 2024: Inflammatory Bowel Diseases
https://read.qxmd.com/read/38507608/clinical-pharmacist-counselling-improves-long-term-medication-safety-and-patient-reported-outcomes-in-anti-tnf-treated-patients-with-inflammatory-bowel-diseases-the-prospective-randomized-adphanced-trial
#35
JOURNAL ARTICLE
Johannes Plechschmidt, Konstantin Fietkau, Tobias Hepp, Peter Dietrich, Sarah Fischer, Sabine Krebs, Markus F Neurath, Frank Dörje, Raja Atreya
BACKGROUND: Antitumor necrosis factor (anti-TNF) antibody treatment has led to marked improvements in the management of patients with inflammatory bowel diseases (IBDs). Nevertheless, anti-TNF therapy is associated with potential adverse drug reactions (ADRs). Our prospective, randomized trial investigated the effect of intensified clinical pharmacist counselling in a multidisciplinary team on medication safety in anti-TNF-treated IBD patients. METHODS: Patients with IBD with ongoing anti-TNF treatment were enrolled in our tertiary center AdPhaNCED trial and randomized to either receive conventional standard of care (control group) or additional clinical pharmacist counselling (intervention group) over 12 months...
March 20, 2024: Inflammatory Bowel Diseases
https://read.qxmd.com/read/38506656/anti-inflammatory-probiotics-hf05-and-hf06-synergistically-alleviate-ulcerative-colitis-and-secondary-liver-injury
#36
JOURNAL ARTICLE
Chunhong Liu, Xiaofen Qi, Xiaolin Liu, Yue Sun, Kaidong Mao, Guiqi Shen, Ying Ma, Qingming Li
Given the limited efficacy and adverse effects associated with conventional drugs, probiotics are emerging as a promising therapeutic strategy for mitigating the chronic nature of ulcerative colitis (UC) and its consequential secondary liver injury (SLI). Limosilactobacillus fermentum HF06 and Lactiplatibacillus plantarum HF05 are strains we screened with excellent anti-inflammatory and probiotic properties in vitro . In this study, the intervention of HF06 and HF05 in combination (MIXL) was found to be more effective in alleviating intestinal inflammation and secondary liver injury in UC mice compared to supplementing with the two strains individually...
March 20, 2024: Food & Function
https://read.qxmd.com/read/38506097/histological-outcomes-and-jak-stat-signalling-in-ulcerative-colitis-patients-treated-with-tofacitinib
#37
JOURNAL ARTICLE
Sara van Gennep, Ivan C N Fung, Djuna C de Jong, Rishand K Ramkisoen, Esmé Clasquin, Jitteke de Jong, Leonie C S de Vries, Wouter J de Jonge, Krisztina B Gecse, Mark Löwenberg, John C Woolcott, Aart Mookhoek, Geert R D'Haens
BACKGROUND AND AIMS: Histological outcomes and JAK-STAT signaling were assessed in a prospective ulcerative colitis (UC) patient cohort after 8 weeks treatment with tofacitinib, an oral Janus kinase (JAK) inhibitor. METHODS: Forty UC patients received tofacitinib 10 mg twice daily for 8 weeks. Treatment response was defined as histo-endoscopic mucosal improvement (HEMI). Histological remission was defined as a Robarts Histopathology Index (RHI) ≤3 points and histological response as 50% decrease in RHI...
March 20, 2024: Journal of Crohn's & Colitis
https://read.qxmd.com/read/38499736/comparative-efficacy-of-subcutaneous-and-intravenous-infliximab-and-vedolizumab-for-maintenance-treatment-of-tnf-naive-adult-patients-with-inflammatory-bowel-disease-a-systematic-literature-review-and-network-meta-analysis
#38
JOURNAL ARTICLE
L Peyrin-Biroulet, P Bossuyt, D Bettenworth, E V Loftus, S I Anjie, G D'Haens, M Saruta, P Arkkila, H Park, D Choi, D- H Kim, W Reinisch
BACKGROUND: Infliximab and vedolizumab are widely used to treat Crohn's disease (CD) and ulcerative colitis (UC). AIMS: This systematic review and network meta-analysis evaluated comparative efficacy of various regimens for intravenous or subcutaneous infliximab and vedolizumab during maintenance treatment in CD and UC. METHODS: Parallel-group randomized controlled trials (RCTs) were identified by a systematic literature review (CRD42022383401) and included if they evaluated therapeutics of interest for maintenance treatment of adults with moderate-to-severe luminal CD or UC and assessed clinical remission between Weeks 30 and 60...
March 18, 2024: Digestive Diseases and Sciences
https://read.qxmd.com/read/38499127/ameliorative-effect-of-an-acidic-polysaccharide-from-phellinus-linteus-on-ulcerative-colitis-in-a-dss-induced-mouse-model
#39
JOURNAL ARTICLE
Jutuan Hu, Yuxia Mei, Heng Zhang, Ji Li, Min Zhang, Yanbin Li, Wendi Yang, Yangyang Liu, Yunxiang Liang
Phellinus linteus, a rare medicinal fungus, displays strong antitumor and anti-inflammatory activities because of its active metabolites, particularly polysaccharides. We investigated effects of P. linteus acidic polysaccharide (PLAP) on amelioration of dextran sodium sulfate (DSS)-induced ulcerative colitis (UC) in a mouse model, and associated mechanisms. PLAP treatment alleviated major UC symptoms (weight loss, reduced food intake, increased disease activity index), and ameliorated histopathological colon tissue damage, reduced levels of pro-inflammatory factors (TNF-α, IL-6, IL-1β), enhanced anti-inflammatory factor IL-10 level, reduced levels of oxidative stress-related enzymes iNOS and MPO, and enhanced expression of tight junction proteins (ZO-1, occludin, claudin-1)...
March 16, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38493113/predictive-biomarkers-for-anti-tnf-alpha-therapy-in-ibd-patients
#40
REVIEW
Manoj Kumar, Selvasankar Murugesan, Nazira Ibrahim, Mamoun Elawad, Souhaila Al Khodor
Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition characterized by severe gut inflammation, commonly presenting as Crohn's disease, ulcerative colitis or categorized as IBD- unclassified. While various treatments have demonstrated efficacy in adult IBD patients, the advent of anti-TNF therapies has significantly revolutionized treatment outcomes and clinical management. These therapies have played a pivotal role in achieving clinical and endoscopic remission, promoting mucosal healing, averting disease progression, and diminishing the necessity for surgery...
March 16, 2024: Journal of Translational Medicine
keyword
keyword
22393
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.